Osaic Holdings
ACAD icon

Osaic Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Osaic Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
9,701
-344
-3% -$7.57K ﹤0.01% 4256
2026
Q1 		$224K Buy
10,045
+127
+1% +$3.04K ﹤0.01% 4061
2025
Q4 		$265K Sell
9,918
-7,132
-42% -$170K ﹤0.01% 3921
2025
Q3 		$394K Buy
17,050
+7,789
+84% +$184K ﹤0.01% 3625
2025
Q2 		$200K Buy
9,261
+202
+2% +$3.75K ﹤0.01% 3941
2025
Q1 		$150K Buy
9,059
+2,914
+47% +$52.9K ﹤0.01% 3865
2024
Q4 		$106K Sell
6,145
-759
-11% -$12.3K ﹤0.01% 4127
2024
Q3 		$106K Buy
6,904
+696
+11% +$11.6K ﹤0.01% 4174
2024
Q2 		$100K Sell
6,208
-2,615
-30% -$42.2K ﹤0.01% 4142
2024
Q1 		$162K Sell
8,823
-20,341
-70% -$504K ﹤0.01% 3870
2023
Q4 		$913K Sell
29,164
-71,142
-71% -$1.7M ﹤0.01% 2605
2023
Q3 		$2.09M Buy
100,306
+68,397
+214% +$1.86M ﹤0.01% 1949
2023
Q2 		$767K Buy
31,909
+7,234
+29% +$161K ﹤0.01% 2758
2023
Q1 		$461K Buy
24,675
+2,689
+12% +$51.2K ﹤0.01% 3165
2022
Q4 		$350K Sell
21,986
-998
-4% -$15.6K ﹤0.01% 3375
2022
Q3 		$377K Buy
22,984
+109
+0.5% +$1.76K ﹤0.01% 3164
2022
Q2 		$322K Sell
22,875
-800
-3% -$14.9K ﹤0.01% 3359
2022
Q1 		$482K Sell
23,675
-2,810
-11% -$68K ﹤0.01% 3254
2021
Q4 		$623K Buy
26,485
+2,399
+10% +$48.3K ﹤0.01% 2853
2021
Q3 		$403K Sell
24,086
-1,593
-6% -$30.7K ﹤0.01% 3258
2021
Q2 		$630K Sell
25,679
-1,267
-5% -$28.6K ﹤0.01% 2771
2021
Q1 		$697K Sell
26,946
-2,806
-9% -$124K ﹤0.01% 2542
2020
Q4 		$1.59M Sell
29,752
-1,216
-4% -$60.4K ﹤0.01% 1636
2020
Q3 		$1.32M Buy
30,968
+6,593
+27% +$285K ﹤0.01% 1621
2020
Q2 		$1.18M Buy
24,375
+545
+2% +$26.2K ﹤0.01% 1635
2020
Q1 		$1.01M Buy
+23,830
New +$982K ﹤0.01% 1530

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings's ACAD Position: Q2 2026 in Review

Osaic Holdings reduced its Acadia Pharmaceuticals (ACAD) stake by 3.4% in Q2 2026, selling an estimated $7.57K and leaving 9,701 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #4256.

Osaic Holdings first reported a position in ACAD in Q1 2020 and has held it in 26 quarters since. The position peaked at $2.09M in Q3 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Osaic Holdings held 9,701 shares of Acadia Pharmaceuticals worth $245K as of Q2 2026.
  • Osaic Holdings sold 344 Acadia Pharmaceuticals shares in Q2 2026, an estimated $7.57K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4256 holding.
  • Osaic Holdings first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Acadia Pharmaceuticals position peaked at $2.09M in Q3 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.